Oculis Secures EMA PRIME Designation for Neuroprotective Candidate Privosegtor
Event summary
- Oculis' Privosegtor received PRIME designation from the EMA for treating optic neuritis, following FDA's Breakthrough Therapy designation in January 2026.
- Phase 2 ACUITY trial data showed substantial improvements in low-contrast visual acuity and neuroprotective benefits.
- PIONEER registrational program, including trials for optic neuritis and NAION, is underway with PIONEER-1 initiated in Q4 2025.
- Privosegtor has Orphan Drug status from both EMA and FDA, highlighting its potential in addressing unmet medical needs.
The big picture
Oculis' PRIME designation for Privosegtor underscores the growing recognition of neuroprotective therapies in treating optic neuritis, a condition with significant unmet medical needs. The dual regulatory support from the EMA and FDA highlights the urgency and importance of addressing this rare, sight-threatening condition. The strategic focus on neuro-ophthalmology positions Oculis to potentially redefine treatment paradigms in this space.
What we're watching
- Regulatory Momentum
- The pace at which Privosegtor advances through global regulatory pathways will determine its market access and commercial potential.
- Clinical Execution
- The success of the PIONEER registrational program will be critical in validating Privosegtor's neuroprotective benefits across multiple indications.
- Market Opportunity
- The potential $7 billion market opportunity in the U.S. alone underscores the strategic importance of Privosegtor's development.